Therapeuticsmd, INC. (TXMD) — 10-K Filings

All 10-K filings from Therapeuticsmd, INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.

10-K Filings (3)

TherapeuticsMD Shifts to Royalty Model, Faces Mayne Pharma Lawsuits — Mar 30, 2026 Risk: high
TherapeuticsMD, Inc. (TXMD) has fully transitioned into a pharmaceutical royalty company by December 31, 2025, following the December 2022 Mayne Transaction. Th
TherapeuticsMD Files 2024 Annual Report — Mar 27, 2025 Risk: medium
TherapeuticsMD, Inc. filed its annual report for the fiscal year ended December 31, 2024. The company, incorporated in Nevada, operates in the pharmaceutical pr
TherapeuticsMD, Inc. Files 2023 Annual Report on Form 10-K — Mar 29, 2024 Risk: low
TherapeuticsMD, Inc. (TXMD) filed a Annual Report (10-K) with the SEC on March 29, 2024. TherapeuticsMD, Inc. filed its annual report on Form 10-K for the fisca

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX